Siegfried Creates Opportunities for Long-term Growth

“The two pharmaceutical manufacturing sites acquired from Novartis, Barberà del Vallès and El Masnou, made a significant contribution to the substantial growth in the reporting period.”

Dear Shareholders 

Siegfried Group’s 2021 financial year represents an important milestone in the history of the company. For the first time, the company reports annual sales of more than one billion Swiss francs. In the year under review, the company successfully continued on its strategic path which, for over ten years, has consistently reported profitable growth. At the same time, the Siegfried Group achieved a pleasing operating result in a very demanding environment characterized by the pandemic.  

At 1.102 billion Swiss francs, sales increased by 30.5 percent (2020: 845.1 million francs). Despite challenging conditions, core EBITDA grew faster than sales, from 149.4 million Swiss francs in the previous year to 207.2 million Swiss francs, 38.8 percent higher than 2020. The core EBITDA margin improved from 17.7 percent to 18.8 percent and is thus within the preliminary target range of around 20 percent. Core net profit grew by 31.4 percent to 95.3 million Swiss francs (2020: 72.5 million Swiss francs), the highest net profit in ­corporate history. Net profit according to Swiss GAAP FER amounted to 96.6 million Swiss francs. The Board of Directors will propose to the Annual General Meeting an increase in the payout to the shareholders to 3.20 Swiss francs per share (2020: 3.00 francs). As in the previous year, the payout will be made by reducing the ­nominal value in the context of a capital ­reduction.